AIM vs BIIB: Which Stock is Better?
Side-by-side comparison of Aim Immunotech Inc and Biogen Inc in 2026
AIM
Aim Immunotech Inc
$0.69
BIIB
Biogen Inc
$189.94
Key Metrics Comparison
| Metric | AIM | BIIB | Winner |
|---|---|---|---|
| Market Cap | $2.79M | $27.88B | BIIB |
| P/E Ratio | N/A | 21.61 | BIIB |
| EPS (TTM) | $N/A | $8.79 | BIIB |
| Revenue Growth | -0.3% | -0.1% | BIIB |
| Gross Margin | 15.2% | 78.9% | BIIB |
Analyze AIM
Full quant analysis
Analyze BIIB
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is AIM or BIIB a better investment?
Comparing AIM and BIIB: Aim Immunotech Inc has a market cap of $2.79M while Biogen Inc has $27.88B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between AIM and BIIB?
AIM (Aim Immunotech Inc) and BIIB (Biogen Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: AIM or BIIB?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: AIM or BIIB?
BIIB has higher revenue growth at -0.1% vs -0.3% for AIM.
Which company is more profitable: AIM or BIIB?
Biogen Inc (BIIB) has higher gross margins at 78.9% compared to 15.2% for AIM.
Which is the larger company: AIM or BIIB?
Biogen Inc (BIIB) is larger with a market cap of $27.88B compared to $2.79M for AIM.
Should I buy AIM or BIIB in 2026?
Both AIM and BIIB have investment merit. AIM trades at $0.69 while BIIB trades at $189.94. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between AIM and BIIB stock?
Key differences: Market Cap ($2.79M vs $27.88B), P/E Ratio (N/A vs 21.6x), Revenue Growth (-0.3% vs -0.1%), Gross Margin (15.2% vs 78.9%).